Public law

H1 Launches Advanced Diversity Insights and Clinical Trial Performance Insights

Retrieved on: 
Monday, March 13, 2023

Additionally, H1 has successfully onboarded its first customer – a top 20 pharmaceutical company – onto the H1 Data Network, a new solution that aggregates sponsor-contributed site and principal investigator (PI) performance data from clinical trial management systems (CTMS) to fuel transparency and clinical trial design.

Key Points: 
  • Additionally, H1 has successfully onboarded its first customer – a top 20 pharmaceutical company – onto the H1 Data Network, a new solution that aggregates sponsor-contributed site and principal investigator (PI) performance data from clinical trial management systems (CTMS) to fuel transparency and clinical trial design.
  • Site feasibility and clinical operations teams at leading pharmaceutical companies use H1 Trial Landscape to discover diverse physician and patient populations and support more representative clinical trial participation.
  • Trial Landscape is an exhaustive clinical trial intelligence repository, incorporating data from public and proprietary sources including over 10 million healthcare providers (HCPs) and over 420,000 clinical trials.
  • Other initiatives supporting clinical trial diversity include the National Institutes of Health’s recently released Minority Health and Health Disparities Strategic Plan 2021-2025, which focuses on improving diversity and inclusion in NIH-funded research with updated clinical trial policies and guidelines.

Stem Cell/Cord Blood Banking Global Market Report 2023: Sector to Reach $16.36 Billion by 2027 at a 10.1% CAGR - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 21, 2023

The main cell types of stem cell/cord blood banking are adult stem cells, umbilical cord blood stem cells, and embryonic stem cells.

Key Points: 
  • The main cell types of stem cell/cord blood banking are adult stem cells, umbilical cord blood stem cells, and embryonic stem cells.
  • Increasing number of cancer patients is a major driver for the stem cell /cord blood banking market.
  • Pairing of cord blood and tissue storage with genetic testing services is an emerging trend in the stem cell/cord blood banking market.
  • 1) By Cell Type: Adult Stem Cells; Umbilical Cord Blood Stem Cells; Embryonic Stem Cells

Notice from the Office of the Secretary - Ontario Securities Commission

Retrieved on: 
Friday, July 30, 2021

TORONTO, July 30, 2021 /CNW/ - The Office of the Secretary issued a Notice of Hearing for a hearing to consider whether it is in the public interest to approve a Settlement Agreement entered into by Staff of the Commission and Trevor Rosborough in the above named matter.

Key Points: 
  • TORONTO, July 30, 2021 /CNW/ - The Office of the Secretary issued a Notice of Hearing for a hearing to consider whether it is in the public interest to approve a Settlement Agreement entered into by Staff of the Commission and Trevor Rosborough in the above named matter.
  • A copy of the Notice of Hearing dated July 30, 2021 is available at www.osc.ca

DGAP-News: Notification of performed Stabilisation Measures pursuant to Article 5 (4) (b) and (5) of Reg. (EU) No 596/2014 (MAR); Article 6 (2) of the Com. Delegated Reg. (EU) 2016/1052

Retrieved on: 
Tuesday, July 27, 2021

Notification of performed Stabilisation Measures pursuant to Article 5 (4) (b) and (5) of Reg.

Key Points: 
  • Notification of performed Stabilisation Measures pursuant to Article 5 (4) (b) and (5) of Reg.
  • (EU) No 596/2014 (MAR); Article 6 (2) of the Com.
  • (EU) 2016/1052 (news with additional features)
    The issuer is solely responsible for the content of this announcement.
  • 26.07.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.

Notice from the Office of the Secretary - Ontario Securities Commission

Retrieved on: 
Monday, July 26, 2021

TORONTO, July 26, 2021 /CNW/ - Take notice that the oral closing submissions in the merits hearing in the above named matter scheduled to be heard on August 13 and 16, 2021 will not proceed as scheduled.

Key Points: 

TORONTO, July 26, 2021 /CNW/ - Take notice that the oral closing submissions in the merits hearing in the above named matter scheduled to be heard on August 13 and 16, 2021 will not proceed as scheduled.

MFDA Hearing Panel issues Reasons for Decision in the matter of Kenneth Clark

Retrieved on: 
Friday, July 23, 2021

TORONTO, July 23, 2021 /CNW/ - A Hearing Panel of the Central Regional Council of the Mutual Fund Dealers Association of Canada ("MFDA") has issued its Reasons for Decision dated July21,2021 ("Reasons for Decision"), in connection with a settlement hearing held by electronic hearing on February 2, 2021, in the matter of Kenneth Ray Clark ("Respondent").

Key Points: 
  • TORONTO, July 23, 2021 /CNW/ - A Hearing Panel of the Central Regional Council of the Mutual Fund Dealers Association of Canada ("MFDA") has issued its Reasons for Decision dated July21,2021 ("Reasons for Decision"), in connection with a settlement hearing held by electronic hearing on February 2, 2021, in the matter of Kenneth Ray Clark ("Respondent").
  • In its Reasons for Decision, the Hearing Panel confirmed the sanctions imposed on the Respondent.
  • A copy of the Reasons for Decision is available on the MFDA website at www.mfda.ca .
  • During the period described in the Reasons for Decision, the Respondent conducted business out of the Brooklin, Ontario area.

MFDA issues Notice of Settlement Hearing in respect of Pauline Arnold

Retrieved on: 
Wednesday, July 21, 2021

The settlement agreement will be between Staff of the MFDA and Pauline Rejeanne Arnold ("Respondent") and involves matters for which the Respondent may be disciplined by a Hearing Panel pursuant to MFDA By-laws.

Key Points: 
  • The settlement agreement will be between Staff of the MFDA and Pauline Rejeanne Arnold ("Respondent") and involves matters for which the Respondent may be disciplined by a Hearing Panel pursuant to MFDA By-laws.
  • MFDA settlement hearings are typically held in the absence of the public pursuant to section 20.5 of MFDA By-law No.
  • A copy of the Notice of Settlement Hearing is available on the MFDA website at www.mfda.ca .
  • During the period described in the Notice of Settlement Hearing, the Respondent conducted business in the Ottawa, Ontario area.

Notice from the Office of the Secretary - Ontario Securities Commission

Retrieved on: 
Wednesday, July 21, 2021

JIUBIN FENG and CIM INTERNATIONAL GROUP INC., File No.

Key Points: 
  • JIUBIN FENG and CIM INTERNATIONAL GROUP INC., File No.
  • 2021-27
    TORONTO, July 21, 2021 /CNW/ - The Office of the Secretary issued a Notice of Hearing on July 21, 2021 setting the matter down to be heard on August 11, 2021 at 10:00 a.m. or as soon thereafter as the hearing can be held in the above named matter.
  • A copy of the Notice of Hearing dated July 21, 2021 and Statement of Allegations dated July 19, 2021 are available at www.osc.ca .

DGAP-News: Notification of performed Stabilisation Measures pursuant to Article 5 (4) (b) and (5) of Reg. (EU) No 596/2014 (MAR); Article 6 (2) of the Com. Delegated Reg. (EU) 2016/1052

Retrieved on: 
Monday, July 19, 2021

Notification of performed Stabilisation Measures pursuant to Article 5 (4) (b) and (5) of Reg.

Key Points: 
  • Notification of performed Stabilisation Measures pursuant to Article 5 (4) (b) and (5) of Reg.
  • (EU) No 596/2014 (MAR); Article 6 (2) of the Com.
  • (EU) 2016/1052 (news with additional features)
    The issuer is solely responsible for the content of this announcement.
  • 19.07.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.

DGAP-News: Notification of performed Stabilisation Measures pursuant to Article 5 (4) (b) and (5) of Reg. (EU) No 596/2014 (MAR); Article 6 (2) of the Com. Delegated Reg. (EU) 2016/1052

Retrieved on: 
Monday, July 12, 2021

Notification of performed Stabilisation Measures pursuant to Article 5 (4) (b) and (5) of Reg.

Key Points: 
  • Notification of performed Stabilisation Measures pursuant to Article 5 (4) (b) and (5) of Reg.
  • (EU) No 596/2014 (MAR); Article 6 (2) of the Com.
  • (EU) 2016/1052 (news with additional features)
    The issuer is solely responsible for the content of this announcement.
  • 12.07.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.